Benzinga
Benzinga
Benzinga
dimanche, septembre 27

HeartSciences Inc

HSCSNASDAQ
Trade with Public
Trade with Public
$4.73
0.102.16%
À la clôture: Sep 25, 5:00 PM EST
$4.66
-0.07-1.48%
Après les heures: Sep 25, 5:46 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerRapport sur les stocks

HeartSciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for HeartSciences (HSCS).

Price Target Range — 5 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingBuy# Analysts2Avg. Consensus PT$10Upside to Avg. PT+114.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Mar 24, 2026Ascendiant CapitalLucas WardPT CutBuy$9→$8
Dec 22, 2025Ascendiant CapitalLucas WardPT RaiseBuy$9→$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $8

Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $9.2 to $8.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on HeartSciences, Raises Price Target to $9.2

Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and raises the price target from $9 to $9.2.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $9

Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $15 to $9.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $14

Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $15 to $14.
Benzinga Newsdesk

PRO
Maxim Group Reiterates Buy on HeartSciences, Maintains $12 Price Target

Maxim Group analyst Allen Klee reiterates HeartSciences (NASDAQ:HSCS) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
Ascendiant Capital Reiterates Buy on Heart Test Laboratories, Maintains $15 Price Target

Ascendiant Capital analyst Lucas Ward reiterates Heart Test Laboratories (NASDAQ:HSCS) with a Buy and maintains $15 price target.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved